Melphalan flufenamide for Multiple myeloma in Relapsing or refractory In combination with dexamethasone [ID3862]
Proposed [GID-TA10744] Expected publication date: TBC
Search results
663 results
-
-
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]
Proposed [GID-TA10745] Expected publication date: TBC
-
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID3860]
Proposed [GID-TA10746] Expected publication date: TBC
-
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]
Proposed [GID-TA10747] Expected publication date: TBC
-
Omburtamab for treating relapsed neuroblastoma [ID1664]
In development [GID-TA10608] Expected publication date: TBC
-
Cardiovascular disease: risk assessment and reduction, including lipid modification
In development [GID-NG10178] Expected publication date: 19 April 2023
-
Bulevirtide for treating chronic hepatitis D [ID3732]
Proposed [GID-TA10652] Expected publication date: TBC
-
Type 1 diabetes in adults: diagnosis and management (update)
In development [GID-NG10159] Expected publication date: TBC
-
Shared decision making
In development [GID-NG10120] Expected publication date: 17 June 2021
-
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1332]
In development [GID-TA10272] Expected publication date: 14 July 2021
-
Atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [ID1674]
In development [GID-TA10543] Expected publication date: TBC
-
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma ID1352
In development [GID-TA10319] Expected publication date: TBC
-
Luspatercept for treating anaemia caused by myelodysplastic syndromes [ID1550]
In development [GID-TA10508] Expected publication date: TBC
-
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]
In development [GID-TA10623] Expected publication date: TBC
-
Nivolumab with ipilimumab for untreated PD-L1 mutation-positive non-small-cell lung cancer [ID1675]
In development [GID-TA10585] Expected publication date: TBC
-
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]
In development [GID-TA10490] Expected publication date: TBC
-
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]
In development [GID-TA10492] Expected publication date: TBC
-
Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667]
In development [GID-TA10567] Expected publication date: 24 November 2021
-
Nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714]
In development [GID-TA10590] Expected publication date: 19 May 2021
-
Liraglutide for managing obesity in people aged 12 to 17 [ID1630]
In development [GID-TA10563] Expected publication date: TBC
-
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma [ID2709]
In development [GID-TA10579] Expected publication date: TBC
-
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia ID1494
In development [GID-TA10424] Expected publication date: TBC
-
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer [ID1665]
In development [GID-TA10550] Expected publication date: TBC
-
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 1 systemic therapy [ID1684]
In development [GID-TA10580] Expected publication date: TBC
-
Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin lymphoma [ID1685]
In development [GID-TA10578] Expected publication date: TBC
-
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596
In development [GID-TA10497] Expected publication date: TBC
-
Nivolumab with ipilimumab for neoadjuvant treatment of early non-small-cell lung cancer [ID3756]
In development [GID-TA10631] Expected publication date: TBC
-
Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353
In development [GID-TA10320] Expected publication date: TBC
-
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]
In development [GID-TA10620] Expected publication date: TBC
-
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]
In development [GID-TA10489] Expected publication date: TBC
-
Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]
In development [GID-TA10377] Expected publication date: TBC
-
ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]
In development [GID-TA10259] Expected publication date: TBC
-
Abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy ID1147
In development [GID-TA10343] Expected publication date: TBC
-
Lysosomal acid lipase deficiency - sebelipase alfa [ID737]
In development [GID-LYSOSOMALACIDLIPASEDEFICIENCYSEBELIPASEALFAID737] Expected publication date: TBC
-
Afamelanotide for treating erythropoietic protoporphyria [ID927]
In development [GID-HST10009] Expected publication date: TBC
-
Third molars (impacted) - prophylactic removal [ID898]
In development [GID-TAG525] Expected publication date: TBC
-
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]
Proposed [GID-TA10453] Expected publication date: TBC
-
Dulaglutide for treating type 2 diabetes [ID1451]
Proposed [GID-TA10439] Expected publication date: TBC
-
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587
Proposed [GID-TA10519] Expected publication date: TBC
-
Multiple sclerosis - sativex [ID387]
In development [GID-TAG368] Expected publication date: TBC
-
Gosuranemab for treating progressive supranuclear palsy [ID1607]
Proposed [GID-TA10553] Expected publication date: TBC
-
Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)
Proposed [GID-TA10306] Expected publication date: TBC
-
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [ID3775]
In development [GID-TA10636] Expected publication date: TBC
-
Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy [ID2700]
Proposed [GID-TA10574] Expected publication date: TBC
-
Onasemnogene abeparvovec for treating spinal muscular atrophy type 1 [ID1473]
In development [GID-HST10026] Expected publication date: 25 March 2021
-
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [ID1536]
In development [GID-TA10466] Expected publication date: 28 April 2021
-
Ravulizumab for treating atypical haemolytic uraemic syndrome (aHUS) [ID1530]
In development [GID-TA10564] Expected publication date: TBC
-
Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]
Proposed [GID-TA10722] Expected publication date: TBC
-
Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]
In development [GID-TA10363] Expected publication date: TBC
-
Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]
In development [GID-TA10609] Expected publication date: TBC